Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.

Status:
Completed

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

This study is designed to evaluate the safety and tolerability of Xalacom in patients with primary glaucoma

Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Timolol